S

Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373

Watchlist Manager
Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373
Watchlist
Price: 5.13 CNY -7.73%
Market Cap: 2.2B CNY
Have any thoughts about
Shanghai MicuRx Pharmaceutical Co Ltd?
Write Note

Shanghai MicuRx Pharmaceutical Co Ltd
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shanghai MicuRx Pharmaceutical Co Ltd
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
S
Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373
Total Equity
ÂĄ834m
CAGR 3-Years
10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Equity
ÂĄ25.1B
CAGR 3-Years
0%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Total Equity
ÂĄ12.4B
CAGR 3-Years
1%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Equity
ÂĄ12.7B
CAGR 3-Years
71%
CAGR 5-Years
57%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Equity
ÂĄ31.5B
CAGR 3-Years
26%
CAGR 5-Years
44%
CAGR 10-Years
29%
Imeik Technology Development Co Ltd
SZSE:300896
Total Equity
ÂĄ6.3B
CAGR 3-Years
12%
CAGR 5-Years
74%
CAGR 10-Years
N/A
No Stocks Found

Shanghai MicuRx Pharmaceutical Co Ltd
Glance View

Market Cap
2.2B CNY
Industry
Biotechnology

Shanghai MicuRx Pharmaceutical Co., Ltd. engages in the experimenting, discovering, and development of innovative medicines. The company is headquartered in Shanghai, Shanghai and currently employs 179 full-time employees. The company went IPO on 2022-08-05. The firm's antibacterial drug product, contezolid tablets, can be applied to treat infections caused by multidrug-resistant gram-positive bacteria. The firm also has a number of new anti-drug-resistant bacteria, kidney cancer, nephritis drugs and anti-new crown drug pipelines in the preclinical stage, including MRX-4, MRX-5, MRX-7, MRX-15, MRX-17 and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
5.58 CNY
Undervaluation 8%
Intrinsic Value
Price
S

See Also

What is Shanghai MicuRx Pharmaceutical Co Ltd's Total Equity?
Total Equity
834m CNY

Based on the financial report for Dec 31, 2023, Shanghai MicuRx Pharmaceutical Co Ltd's Total Equity amounts to 834m CNY.

What is Shanghai MicuRx Pharmaceutical Co Ltd's Total Equity growth rate?
Total Equity CAGR 3Y
10%

Over the last year, the Total Equity growth was -31%. The average annual Total Equity growth rates for Shanghai MicuRx Pharmaceutical Co Ltd have been 10% over the past three years .

Back to Top